Navigation Links
Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
Date:12/10/2008

bio.com/" target="_new">http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that certain closing conditions required to obtain the initial funding of $5 million will not be achieved and the risk that we will not satisfy the additional conditions to exercise the option for the second $5 million tranche. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to,
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... ... Prize in Chemistry published papers on their award-winning work based on data collected at the ... ... Nobel Prize in Chemistry published papers on their award-winning work based on data collected at ...
... Inc. (Nasdaq: LXRX ) today announced that it ... conditions, 27,500,000 shares of its common stock pursuant to ... are being offered through the underwriters and 11,087,387 shares ... Lexicon also intends to grant the underwriters a ...
... ... President Obama , ... Argonne, Ill. (Vocus) October 7, 2009 -- The IBM Blue Gene series of energy-efficient ... President Barack Obama as a Medal of Technology and Innovation award-winner on October 7 ...
Cached Biology Technology:Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel 2Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel 3Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 2Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 4
(Date:4/16/2014)... in museum collections two new species of yellow-shouldered bats have been ... The Field Museum of Natural History and described in the open ... to the genus Sturnira are part of a recent ... the third one still waiting to be officially announced. , Up ...
(Date:4/16/2014)... leaf looks like one seamless surface; however, up close, ... patchwork of cells in a variety of shapes and ... their own unique forms, Caltech biologist Elliot Meyerowitz, postdoctoral ... shape-controlling factors in pavement cells, which are puzzle-piece-shaped epithelial ...
(Date:4/16/2014)... , Professor Nicolas Doucet of the Centre INRSInstitut Armand-Frappier has ... Health (NIH) in the amount of nearly US$600,000. The 5-year ... tiny proteins called RNases and to explore their biomedical potential ... and asthma. , "Receiving a grant at this ...
Breaking Biology News(10 mins):Two new species of yellow-shouldered bats endemic to the Neotropics 2For cells, internal stress leads to unique shapes 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2
... BEDFORD, Mass., July 16 Aware, Inc. (Nasdaq: ... scheduled a conference call to discuss the company,s operating results for the ... Time. CEO Michael Tzannes and CFO Rick Moberg will host the earnings ... being webcast by Thomson and can be accessed on the Investor Relations ...
... Blacksburg, Va. -- Ten articles describing how a universal ... study of the microbial world have been published in ... co-edited by Virginia Bioinformatics Institute professor Brett Tyler. The ... a shared vocabulary to describe disease-related and beneficial interactions ...
... early-life experience sticks with them into adulthood and may render ... aging, according to a new UBC study. A team ... genome-wide profiling in 103 healthy adults aged 25-40 years. ... high in early-life socioeconomic circumstances related to income, education and ...
Cached Biology News:Aware, Inc. Announces Q2'09 Earnings Conference Call 2Reviews of microbial gene language published in special issue of Trends in Microbiology 2Reviews of microbial gene language published in special issue of Trends in Microbiology 3Reviews of microbial gene language published in special issue of Trends in Microbiology 4Early-life experience linked to chronic diseases later in life: UBC research 2
Agarose II (Low Melt)...
...
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
... antibody raised against a partial ... Immunogen: PPP4C (NP_002711, 218 ... recombinant protein with GST tag. ... NM_002720 ...
Biology Products: